Join us for a unique summit exploring the current and future applications of artificial intelligence (AI) in diagnosing and treatment planning for dry age-related macular degeneration (AMD) and geographic atrophy (GA).

This cutting-edge event brings together industry experts, academia, and retina specialists for an insightful day focused on how AI is transforming retina practices.

RetinAI

Cole Eye Institute

Topcon Healthcare Inc

Heidelberg

Macuject

RetInSight

Doheny Eye Institute

deepeye

Zeiss

Dr. David C. Rhew, Chief Medical Officer of Microsoft, will share insights on the future of AI in healthcare and its impact on eye care.

Hear from leaders in AI diagnostics and algorithm development. Each speaker will give a 5-minute presentation on the latest AI advancements from both industry and academia.

Join a panel of leading retina specialists as they discuss how AI technologies will be seamlessly integrated into everyday retina practices, enhancing patient care.

Engage in a focused session designed for doctors, exploring how AI will support—not replace—clinical decision-making in the management of retina diseases.

Welcome Registration & Dinner Reception

Welcome address, opening survey questions, and review of global clinical trends survey data on AI

Anat Loewenstein, MD

Panel Discussion: 

Collaborating with physicians, companies and academic leaders on the future of AI in GA

Keynote Lecture: Future of AI in Healthcare

David C. Rhew, MD
Global Chief Medical Officer, Microsoft

How AI is Being Integrated into Diagnostics and Algorithms

Guest Presentations from:
Heidelberg

Cole Eye Institute
Topcon
RetinAI
RetinSight
MacuJect

Doheny Eye Institute

Zeiss

Deepeye

Breakout

Physician Breakout

• Pro/Con: Future of human clinical decision making
• Pro/Con: AI as a predictive tool to engage treatment

Final Panel Discussion: Breakout highlights, audience questions, and final take aways

Conclusions

This program is independently supported by Astellas Pharma with guest presentations from Heidelberg, Cole Eye Institute, Topcon Healthcare Inc, RetinAI,  RetinSight, Macuject, Doheny Eye Institute, Zeiss, and Deepeye.

The Fundingsland Group (TFG) is an independent medical education company that believes in providing compelling, compliant, and effective peer-to-peer education that addresses gaps in clinical knowledge, opinions, and practice patterns. Through a unique, data-driven process, TFG identifies key educational needs and evaluates progress towards meeting clearly defined goals. By strategically collaborating with education partners and industry experts, we create customized education programs that seek to change opinions, affect practice patterns and, ultimately, improve patient care. 

Copyright © 2024 The Fundingsland Group. All rights reserved.